Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Other Accumulated Expenses (2023 - 2025)

Contineum Therapeutics' Other Accumulated Expenses history spans 3 years, with the latest figure at $50000.0 for Q3 2025.

  • Quarterly Other Accumulated Expenses fell 40.48% to $50000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $50000.0 through Sep 2025, down 40.48% year-over-year, with the annual reading at $124000.0 for FY2024, 22.77% up from the prior year.
  • Other Accumulated Expenses came in at $50000.0 for Q3 2025, down from $109000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $2.5 million in Q1 2025 to a low of $30000.0 in Q1 2024.
  • The 3-year median for Other Accumulated Expenses is $92500.0 (2023), against an average of $378625.0.
  • The largest YoY upside for Other Accumulated Expenses was 8163.33% in 2025 against a maximum downside of 40.48% in 2025.
  • Contineum Therapeutics' Other Accumulated Expenses stood at $101000.0 in 2023, then increased by 22.77% to $124000.0 in 2024, then plummeted by 59.68% to $50000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTNM's Other Accumulated Expenses are $50000.0 (Q3 2025), $109000.0 (Q2 2025), and $2.5 million (Q1 2025).